MARTI TECHNOLOGIES INC
MRTNYSE AMERICANTrading Snapshot
- Day Range
- $2.04 – $2.06
- 52-Week Range
- $1.12 – $2.75
- Volume (shares)
- 5,448
- Avg Volume (shares)
- —
- Shares Outstanding
- 86.0M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- $39M
- Last Q Revenue
- $20M
- P/E Ratio
- —
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-0.76
- Dividend Yield
- —
- Dilution (1yr)
- +40.7%
MARTI TECHNOLOGIES INC
MRT
StockOtter · stockotter.spaceAbout MARTI TECHNOLOGIES INC
Marti Technologies Inc. (MRT), headquartered in Istanbul, Turkey, specializes in urban mobility. The company provides city-dwellers across Turkey with a range of transportation solutions via its proprietary mobile application. This platform offers access to a diverse fleet of shared electric vehicles, including e-mopeds, e-bikes, and e-scooters. Marti Technologies was established in 2018.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader
Marti Technologies Expands Ride-Hailing Service to 40 Cities Across Türkiye
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced the launch of its ride-hailing service in 10 additional cities ac
MHI Receives Follow-up Order for 8 Two-Car Trains for Singapore's Sengkang-Punggol LRT (SPLRT)
- MHI secures another contract following the 2023 order for 8 additional two-car trains, bringing the total number of trainsets to 33- MHI Group has contributed
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosc
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that managem